Letters to the Editor

A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Dept. of Hematology, St Vincent's Hospital, University of Melbourne,
Illawarra Cancer Care Centre, Wollongong, NSW, Australia
Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
Molecular Oncology and Cancer Immunology, Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia
Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
Department of Hematology, Blacktown and Mount Druitt Hospitals, Blacktown, NSW, Australia
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
Early Phase Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
MD Anderson Cancer Center, Gilbert, AZ
Department of Hematology, City of Hope National Medical Center, Duarte, CA
Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
Sanofi, Research and Development, Cambridge, MA
Sanofi, Research and Development, Cambridge, MA
Sanofi, Research and Development, Reading
Sanofi, Research and Development, Vitry-sur-Seine
Sanofi, Research and Development, Vitry-sur-Seine
Department of Hematology, University Hospital of Nantes, Nantes, France
Haematologica Early view Aug 15, 2024 https://doi.org/10.3324/haematol.2023.284730